Dementia Discovery Fund is a specialist venture capital fund that invests in novel science to create meaningful new medicines.
Business Model:
Revenue: $65.1M
Employees: 51-200
Address: 201 Washington St Ste 3900
City: Boston
State: MA
Zip: 02108
Country: US
The Dementia Discovery Fund is the world’s largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The DDF has raised a total of £250 million to develop novel disease-modifying therapeutics for all forms of dementia. They have a mandate to validate novel hypotheses and expand the breadth of targets and mechanisms in development for dementia over the 15 year life of the fund. This enables the DDF to invest in truly novel, early-stage projects starting from target identification, and explore novel biological insights for translation into disease-modifying drugs.
Contact Phone:
+16173678100
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2019 | Ribometrix | Equity | 7.8M |
6/2016 | Gen2 Neuroscience | Seed Round | - |
1/2018 | Tiaki Therapeutics | Seed Round | - |
11/2018 | Caraway Therapeutics | Series A | 23M |
4/2020 | Cerevance | Series B | 65M |
1/2020 | Transine Therapeutics | Seed Round | - |
5/2021 | Cumulus Neuroscience | Venture Round | 8.3M |
5/2020 | QurAlis | Series A | 0 |
2/2018 | Cerevance | Venture Round | - |
11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
4/2018 | Evelo Biosciences | Venture Round | 47.5M |
5/2017 | Cerevance | Series A | 5M |
3/2017 | Autifony Therapeutics | Venture Round | 1.6M |
12/2020 | BrainWaveBank | Convertible Note | 8M |
11/2021 | Nitrase Therapeutics | Series A | 0 |
8/2019 | AstronauTx | Venture Round | 7.9M |
5/2021 | Therini Bio | Seed Round | 0 |
7/2019 | Therini Bio | Seed Round | 9.3M |
11/2018 | Ribometrix | Series A | 30M |
6/2017 | Mitoconix Bio | Series A | 20M |
12/2022 | Amphista Therapeutics | Series B | - |
4/2020 | Nitrase Therapeutics | Series A | 38M |
1/2020 | AviadoBio | Seed Round | 15.9M |
5/2022 | Transine Therapeutics | Seed Round | 0 |
1/2016 | Alector | Series D | 29.5M |
2/2023 | Cerevance | Series B | 0 |
4/2023 | Therini Bio | Series A | 0 |
12/2021 | AviadoBio | Series A | 0 |
3/2023 | QurAlis | Series B | 0 |
10/2017 | Ribometrix | Seed Round | 7.5M |
6/2021 | Transine Therapeutics | Seed Round | 0 |
4/2021 | Alchemab Therapeutics | Series A | 82.7M |
9/2019 | Amathus Therapeutics | Venture Round | - |
1/2019 | LOQUS23 THERAPEUTICS | Seed Round | 5.7M |
1/2010 | Nordic | Seed Round | - |
4/2023 | Therini Bio | Series A | 0 |
3/2023 | QurAlis | Series B | 0 |
2/2023 | Cerevance | Series B | 0 |
12/2022 | Amphista Therapeutics | Series B | - |
5/2022 | Transine Therapeutics | Seed Round | 0 |
12/2021 | AviadoBio | Series A | 0 |
11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
11/2021 | Nitrase Therapeutics | Series A | 0 |
6/2021 | Transine Therapeutics | Seed Round | 0 |
5/2021 | Therini Bio | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|